Skip to content
The new prime DX assay is based on advanced molecular technology using hybridization capture NGS with UMIs. The test utilizes the Oncology Multi-Gene Variant Assay (GenePlus) which is a qualitative in vitro diagnostic test (CE-IVD) that detects variants in 1021 tumor-related genes and gene rearrangements
/ fusions in 38 genes.
It analyzes biomarkers for immunotherapy response, including detection of HLA
and biomarkers for chemotherapy response. MGI-DNBSEQ-G400 is a CE-IVD platform which allows the simultaneous processing of multiple samples with high sensitivity and specificity thus producing
faster, reliable results at a lower cost
2020 Genekor Medical S.A.. All Rights Reserved.
Web Design
We use cookies that are absolutely necessary for the operation of this website and the provision of functions that you requested. These cookies remain enabled throughout your visit. Analysis cookies are installed in order to enhance your overall experience of browsing the site, to measure our audience, to collect useful information that will allow us to offer you information tailored to your interests. These cookies will be activated only if you give us your consent. By clicking "Accept " you give your consent to the use of analytics cookies; by clicking on "REJECT " or by continuing to browse the website without any choice, only the technically necessary cookies will be stored in your browser. Learn more about cookies at our Cookies Policy and click on Cookie settings to set and / or modify your cookie preferences. In case you would like to be informed about the use of cookies please contact the following email: dataprotection@genekor.com ACCEPT REJECT Privacy & Cookies Policy